Skip NavigationSkip to Content

Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents

  1. Author:
    Oliva, Paola
    Romagnoli, Romeo [ORCID]
    Cacciari, Barbara
    Manfredini, Stefano [ORCID]
    Padroni, Chiara
    Brancale, Andrea [ORCID]
    Ferla, Salvatore [ORCID]
    Hamel,Ernest
    Corallo, Diana
    Aveic, Sanja [ORCID]
    Milan, Noemi [ORCID]
    Mariotto, Elena [ORCID]
    Viola, Giampietro [ORCID]
    Bortolozzi, Roberta [ORCID]
  2. Author Address

    Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy., Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy., Medicinal Chemistry Department, Integrated Drug Discovery, Aptuit-An Evotec Company, Via A. Fleming, 37135 Verona, Italy., School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK., Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea SA2 8PP, UK., Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA., Laboratory of Target Discovery and Biology of Neuroblastoma, Istituto di Ricerca Pediatrica (IRP), Fondazione Citt 224; della Speranza, Padova, Corso Stati Uniti 4, 35128 Padova, Italy., Hemato-Oncology Lab, Department of Woman 39;s and Child 39;s Health, University of Padova, 35131 Padova, Italy., Laboratory of Experimental Pharmacology, Istituto di Ricerca Pediatrica (IRP), Fondazione Citt 224; della Speranza, Padova, Corso Stati Uniti 4, 35128 Padova, Italy.,
    1. Year: 2022
    2. Date: Jun 02
    3. Epub Date: 2022 06 02
  1. Journal: Pharmaceutics
    1. 14
    2. 6
  2. Type of Article: Article
  1. Abstract:

    Two different series of fifty-two compounds, based on 3 39;,4 39;,5 39;-trimethoxyaniline (7a-ad) and variably substituted anilines (8a-v) at the 7-position of the 2-substituted-[1,2,4]triazolo [1,5-a]pyrimidine nucleus, had moderate to potent antiproliferative activity against A549, MDA-MB-231, HeLa, HT-29 and Jurkat cancer cell lines. All derivatives with a common 3-phenylpropylamino moiety at the 2-position of the triazolopyrimidine scaffold and different halogen-substituted anilines at its 7-position, corresponding to 4 39;-fluoroaniline (8q), 4 39;-fluoro-3 39;-chloroaniline (8r), 4 39;-chloroaniline (8s) and 4 39;-bromoaniline (8u), displayed the greatest antiproliferative activity with mean IC50 39;s of 83, 101, 91 and 83 nM, respectively. These four compounds inhibited tubulin polymerization about 2-fold more potently than combretastatin A-4 (CA-4), and their activities as inhibitors of [3H]colchicine binding to tubulin were similar to that of CA-4. These data underlined that the 3 39;,4 39;,5 39;-trimethoxyanilino moiety at the 7-position of the [1,2,4]triazolo [1,5-a]pyrimidine system, which characterized compounds 7a-ad, was not essential for maintaining potent antiproliferative and antitubulin activities. Compounds 8q and 8r had high selectivity against cancer cells, and their interaction with tubulin led to the accumulation of HeLa cells in the G2/M phase of the cell cycle and to apoptotic cell death through the mitochondrial pathway. Finally, compound 8q significantly inhibited HeLa cell growth in zebrafish embryos.

    See More

External Sources

  1. DOI: 10.3390/pharmaceutics14061191
  2. PMID: 35745764
  3. PMCID: PMC9230136
  4. PII : pharmaceutics14061191

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel